Paula Gónzález-Alonso

Author

Hospital Universitario Fundación Jiménez Díaz ORCID

Also Known As

P González-Alonso, P. Gonzalez-Alonso, P. González-Alonso, Paula Gonzalez-Alonso, Paula Gonzalez‐Alonso, Paula González Alonso, Paula González-Alonso, Paula González‐Alonso, Paula Gónzález-Alonso

Publications

667

Citations

H-Index

Concepts

All Affiliations

Hospital Universitario Fundación Jiménez Díaz Universidad Autónoma de Madrid Hospital Del Mar INCLIVA Health Research Institute Universitat Pompeu Fabra

About

Paula Gónzález-Alonso is an author at Hospital Universitario Fundación Jiménez Díaz specializing in medicine, tumor biology, and molecular biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	231
2	Natural Sciences	2	2	150
3	Cell Biology	2	2	51
4	Chemical Biology	2	2	150
5	Health Sciences	1	1	30

Paula Gónzález-Alonso

Publications

584

Citations

H-Index

Page 1

	Year	Citations
Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer MohammadA Sabbaghi, Gabriel Gil‐Gómez, Cristina Guardia, Clinical Cancer Research	2017	94
Covalent inhibition of NSD1 histone methyltransferase Huang Huang, Christina A. Howard, Sergei Zari, Nature Chemical Biology Histone ModificationsChromatinChromatin RemodelingNatural SciencesEpigenetic Change	2020	86
The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 gene Eduardo Tormo, Anna Adam‐Artigues, Sandra Ballester, Scientific Reports	2017	72
Small-molecule inhibitors targeting Polycomb repressive complex 1 RING domain Shirish Shukla, Weijiang Ying, Felicia Gray, Nature Chemical Biology Natural SciencesMedicineRing DomainMolecular BiologyBiomolecular Interaction	2021	64
Generation, characterization, and maintenance of trastuzumab-resistant HER2+ breast cancer cell lines. Sandra Zazo, Paula Gónzález-Alonso, Ester Martı́n-Aparicio, PubMed	2016	48
Autocrine CCL5 Effect Mediates Trastuzumab Resistance by ERK Pathway Activation in HER2-Positive Breast Cancer Sandra Zazo, Paula Gónzález-Alonso, Ester Martı́n-Aparicio, Molecular Cancer Therapeutics	2020	40
The Hippo Pathway Transducers YAP1/TEAD Induce Acquired Resistance to Trastuzumab in HER2-Positive Breast Cancer Paula Gónzález-Alonso, Sandra Zazo, Ester Martı́n-Aparicio, Cancers	2020	34
Activation of the Tumor Suppressor PP2A Emerges as a Potential Therapeutic Strategy for Treating Prostate Cancer Ion Cristóbal, Paula Gónzález-Alonso, Lina Daoud, Marine Drugs UrologySignal TransductionSignaling PathwayPp2a ActivityMedicine	2015	30
MicroRNA-31 Emerges as a Predictive Biomarker of Pathological Response and Outcome in Locally Advanced Rectal Cancer Cristina Caramés, Ion Cristóbal, Víctor Moreno, International Journal of Molecular Sciences Surgical OncologyPathologyCancer BiologyTumor BiologyGastrointestinal Oncology	2016	30
Downregulation of microRNA-199b predicts unfavorable prognosis and emerges as a novel therapeutic target which contributes to PP2A inhibition in metastatic colorectal cancer Ion Cristóbal, Cristina Caramés, Raúl Rincón, Oncotarget	2016	22

Page 1